Efficacy is the most common trigger for a switch, though the switch patterns differ dramatically depending on whether it was a primary vs. secondary efficacy issue, with other factors, such as patient and payer influence, also playing a role. Reasons for new brand choice also vary between classes of treatment. View complimentary data highlights full 2018 report below.
According to the recent audit, ICER's recognition of progressive disease as "active" or "not active" is a clinically relevant distinction due to the significant differences in patient demographics, disability progression, and treatment patterns between the active and not active SPMS subgroups.
After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi / Regeneron’s Dupixent. In Spherix’s fourth quarter update of RealTime Dynamix™: Atopic Dermatitis (US), collaborating dermatologists indicated that the first biologic to treat moderate-to-severe atopic dermatitis has consistently exceeded expectations, and satisfaction with the IL-4/13 inhibitor remains extremely high.
Driven by the availability of Merck KGaA’s Mavenclad and substantial uptake of Biogen’s Tecfidera, the oral disease-modifying therapy (DMT) class share of DMT-treated multiple sclerosis (MS) patients increased significantly in the EU over the past six months, putting significant pressure on Teva’s Copaxone.